Scientists have closely monitored the variant this summer to assess its risk of competing against BA.5 — the nation’s dominant strain — or causing more severe disease. Emerging research suggests the variant may not pose a large threat to public health.
A study published Sept. 1 in The Lancet Infectious Diseases found BA.2.75 was not more immune evasive than BA.5 and is still responsive to the monoclonal antibody treatments Evusheld and bebtelovimab. A separate study published in the journal found that antibody escape was an overall less pronounced characteristic of BA.2.75 compared with BA.4 and BA.5.
Below is a breakdown of U.S. states reporting BA.2.75 cases, based on a dashboard run by Raj Rajnarayanan, PhD, assistant dean of research and associate professor in the department of basic sciences at the New York Institute of Technology College of Osteopathic Medicine at Arkansas State University in Jonesboro. The dashboard uses data from GISAID, a global data-sharing platform for viruses.
California — 75
New York — 51
New Jersey — 46
Washington — 34
Texas — 28
Illinois — 22
North Carolina — 20
Arizona — 18
Georgia — 13
Maryland — 12
Michigan — 11
Ohio — 11
Virginia — 11
Wisconsin — 9
Pennsylvania — 9
Connecticut — 8
Massachusetts — 7
Indiana — 6
Florida — 6
Minnesota — 5
District of Columbia — 5
Colorado — 5
Iowa — 4
Nevada — 3
Nebraska — 3
Tennessee — 2
Maine — 2
Kentucky — 2
Kansas — 2
Delaware — 2
Rhode Island — 1
Missouri — 1
Hawaii — 1
Alaska — 1
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
